NASDAQ · Biotechnology

OnKure Therapeutics, Inc. (OKUR) Stock

$2.30 -2.13% NASDAQ: OKUR Healthcare

Valuation

MetricValue
Price$2.30
Market Cap$93.14M
P/E Ratio-0.73
P/B Ratio0.74
P/S Ratio0.00
EPS (TTM)$-4.40
52-Week High$5.38
52-Week Low$2.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.02%
ROA-32.73%
ROCE-35.98%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio10.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-40.0M$-30.0M$-37.0M$-54.0M$-63.0M
Net Profit$-40.0M$-30.0M$-35.0M$-53.0M$-60.0M
EPS$-21.92$-2.21$-2.65$-3.95$-4.40
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$154.0M$16.0M$36.0M$115.0M$62.0M
Total Liabilities$7.0M$70.0M$138.0M$11.0M$6.0M
Cash$125.0M$12.0M$30.0M$111.0M$59.0M
Borrowings$0$1.0M$1.0M$1.0M$1.0M

Latest News

OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near MarketBeat · Jul 15, 2026 OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 GlobeNewswire · Jul 2, 2026 OnKure Therapeutics Reports First Quarter 2026 Financial Results GlobeNewswire · May 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-38.0M$-27.0M$-35.0M$-51.0M$-52.0M
Investing Cash Flow$-24.0M$-2.0M$0$16.0M$0
Financing Cash Flow$0$-1.0M$-1.0M$51.0M$0
Net Cash Flow$71.0M$-2.0M$18.0M$81.0M$-52.0M
Free Cash Flow$-38.0M$-28.0M$-35.0M$-51.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA1.07
FCF Yield-46.17%
Quick Ratio26.75
Interest Coverage-7767.50
Return 1Y68.73%
Return 3Y-94.25%
Return 5Y-95.21%

Ownership

Insiders Held10.48%
Institutions Held76.71%
Institutions Float Held85.69%
Institutional HolderSharesReport Date
RA Capital Management, L.P.3,998,3332026-03-31
Acorn Capital Advisors, LLC 2,839,6742026-03-31
StepStone Group LP2,660,6122026-03-31
Adar1 Capital Management, LLC 2,434,9412026-03-31
Prosight Management, Lp2,154,3812026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGSAligos Therapeutics, Inc. $5.39 +1.41% -0.76 $33.32M 0.00%
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.08 +0.93% 3.25 $33.88M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVMCel-Sci Corporation $1.95 -8.45% -0.90 $13.40M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%

About OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. is led by CEO Nicholas A. Saccomano, employs 46 people, headquartered in US, publicly traded since 2021.

OnKure Therapeutics, Inc. (OKUR) stock trades at $2.30 with a market capitalization of $93.14M. The stock is valued at a price-to-earnings (P/E) ratio of -0.73, price-to-book of 0.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.17 and $5.38, and currently trades 57.2% below its 52-week high.

On profitability, OnKure Therapeutics, Inc. generates a return on equity (ROE) of -49.02%, return on capital employed of -35.98%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.19 -0.04% JNJ Johnson & Johnson $259.19 +1.06% ABBV AbbVie Inc. $275.55 +1.15% MRK Merck & Company, Inc. Common Stock (new) $145.07 +1.89% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.63 +1.53% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $656.82 +0.74% AMGN Amgen Inc. $411.80 +1.07% GILD Gilead Sciences, Inc. $149.65 +1.73% ABT Abbott Laboratories $100.20 +1.74% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides